Abstract:Impressive outcomes in therapeutic radiation oncology have been achieved in the past decade through the development of advanced computer technology and imaging methods, such as intensity modulated radiotherapy. Ideally, radiotherapy treatment delivers a high dose to the tumor while sparing the surrounding healthy tissues and organs at risk from radiation damage. Spatiotemporal Fractionated Radiotherapy has emerged as an innovative technique that delivers different dose distributions to different parts of the tumor in order to achieve high doses to the target while ensuring a low dose-bath in the surrounding normal tissue. Spatiotemporally fractionated regimens showed in silico up to 10 - 15% sparing of normal tissue from radiation damage, while ensuring isoeffective tumor control compared to conventionally fractionated regimens. However, prior to advancing spatiotemporal fractionation to the clinical level, it is important to probe the validity of the main assumption of spatiotemporal fractionation derived from the Biologically Effective Dose (BED) model: two different fractionation schemes that implement a high and a low dose will lead to equivalent clinical effects, regardless of dose-treatment sequence. A tumor growth delay study was performed in a subcutaneous immunocompetent murine tumor model (MC38-tumor cell derived) receiving two different fractionation regimens. Particularly, tumors belonging to the two treatment groups received the same dose combination - a high (12 Gy) and a low (6 Gy) dose fraction separated by 72 hours - with the doses delivered in opposite order in the two treatment groups. The same experimental outline was performed in a subcutaneous immunodeficient murine tumor model derived from the same tumor cells. Tumors were also characterized by immunophenotyping analysis seven days after first irradiation. Even though the two regimens deliver the same physical dose to the tumor - and would be considered equivalent according to the BED model - different tumor growth delays were observed in a time window of 30 days after first irradiation depending on the treatment group. Such differences were observed in the immunocompetent model but not in the immunodeficient model. The immunophenotyping results showed immunostimulatory vs immunosuppressive phenotypes of the tumor microenvironment depending on the order of the treatment doses. An additional tumor growth delay study including immune checkpoint inhibitors confirmed the fundamental role of the immune system with the differential efficacy outcomes of the two regimens. Overall, these intriguing results suggest that a differential radiotherapy-induced immune response to different doses of ionizing radiation plays an important role in the treatment outcome and asks for re-evaluation of the BED model taking scheduling-dependent parameters into consideration. Citation Format: Irene Vetrugno, Irma Telarovic, Nathan Torelli, Jan Unkelbach, Martin Pruschy. Spatiotemporal fractionation: An innovative concept of fractionated radiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2879.

Computational Approach for Spatially Fractionated Radiation Therapy (SFRT) and Immunological Response in Precision Radiation Therapy

Divide and conquer: spatially fractionated radiation therapy

Spatially fractionated radiation therapy: a critical review on current status of clinical and preclinical studies and knowledge gaps

The Peaks and Valleys of Photon Versus Proton Spatially Fractionated Radiotherapy

On the significance of the different geometrical and dosimetric parameters in microbeam and minibeam radiation therapy a retrospective evaluation

Overview and recommendations for prospective multi-institutional clinical trials of Spatially Fractionated Radiation Therapy (SFRT)

Assessing dosimetric advancements in spatially fractionated radiotherapy: From grids to lattices

Abstract 2879: Spatiotemporal fractionation: An innovative concept of fractionated radiotherapy

Precision Radiation for Brain Metastases With a Focus on Hypofractionated Stereotactic Radiosurgery

Spatially fractionated GRID radiation potentiates immune-mediated tumor control

Mathematical Modeling of the Synergetic Effect between Radiotherapy and Immunotherapy

Real-World Implementation of Simulation-Free Radiation Therapy (SFRT-1000): A Propensity Score-Matched Analysis of 1000 Consecutive Palliative Courses Delivered in Routine Care

A Partial Tumor Irradiation Approach for Complex Bulky Disease

Prospect of radiotherapy technology development in the era of immunotherapy

Future of Team-based Basic and Translational Science in Radiation Oncology

The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity

Recent advances in radiation oncology

A biomathematical model of tumor response to radioimmunotherapy with $α$PDL1 and $α$CTLA4

Precision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors

Rethinking the potential role of dose painting in personalized ultra-fractionated stereotactic adaptive radiotherapy

Nimg-55. Developing A Computational Pipeline To Forecast And Spatially Map High-Grade Glioma Response To Radiotherapy Using Biophysical Models And Data-Driven Statistical Analysis